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Introduction
Inflammatory demyelinating diseases of the 
central nervous system (CNS) comprise a broad 
spectrum of mechanistically heterogeneous dis-
orders of which multiple sclerosis (MS) is the 
most common [Meinl et al. 2010]. There is strong 
evidence based on histopathological investiga-
tions and clinical response to plasma exchange 
[Keegan et al. 2005] that antibody-dependent 
mechanisms contribute to the pathogenesis in at 
least a subset of patients with CNS inflammation 
[Meinl et al. 2006]. The recently discovered aqua-
porin (AQP)4-specific autoantibodies allow the 
differentiation of neuromyelitis optica (NMO) 
from MS [Weinshenker et al. 2006]. It is tempting 
to speculate that certain subsets of MS patients 
can be identified based on their autoantibody 
profile. Myelin oligodendrocyte glycoprotein 
(MOG) is one of the best studied candidates, and 
is the focus of this review.
Historically: why is MOG interesting as 
a target?
The interest in MOG is based on animal 
experiments showing that MOG is a target 
of demyelinating antibodies. Initially, it was 
described that CNS homogenate contains a target 
of antibodies mediating complement-dependent 
demyelination in guinea pigs [Lebar et al. 1976, 
1986]. A monoclonal antibody (mAb), 8-18C5 
against rat cerebellar glycoproteins was raised in 
mice [Linnington et al. 1984] and used to define 
a glycoprotein in CNS myelin that was later 
named MOG [Linington and Lassmann, 1987]. 
With the help of this mAb, rat MOG cDNA was 
isolated and subsequently sequenced [Gardinier 
et al. 1992]. The sera of experimental autoim-
mune encephalomyelitis (EAE) guinea pigs were 
shown to have a demyelinating activity which was 
correlated to anti-MOG antibody titers [Linington 
and Lassmann, 1987].
Lessons from animal models
MOG can be involved in CNS autoimmunity in 
principally two different ways. First, MOG-
specific T cells evoke CNS inflammation. Second, 
anti-MOG antibodies lead to the induction of 
demyelination. Demyelination is a characteristic 
feature of MS lesions indicated by the presence of 
naked demyelinated axons.
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The development of encephalitogenic T cells and 
demyelinating antibodies upon immunization 
with MOG depends largely on the strain of mice 
or rats. In Dark Agouti (DA) rats, immunization 
with MOG in complete Freund’s adjuvant (CFA) 
results in a prominent T-cell response with only 
slight demyelination [Storch et al. 1998]. Brown 
Norway (BN) rats, on the other hand, develop a 
strong antibody response upon active immuniza-
tion with MOG and incomplete Freund’s adju-
vant (IFA) [Storch et al. 1998]. Immunizing 
Lewis rats with murine MOG and CFA causes a 
rather mild form of EAE, characterized by occa-
sional focal demyelination with only small num-
bers of T cells in the CNS, suggesting that 
MOG is a poor encephalitogen in the Lewis rat 
[Adelmann et al. 1995]. It has been proposed that 
this difference is due to higher expression of 
MOG in the CNS of BN rats compared with 
Lewis rats and that this increase in protein expres-
sion is caused by polymorphisms in the non-coding 
region of the MOG gene [Pagany et al. 2003].
SJL/J mice, but not C57Bl/6 mice, are able to 
mount a pathogenic anti-MOG antibody response 
upon active immunization with recombinant rat 
MOG and IFA [Bourquin et al. 2003]. The inabil-
ity of C57BL/6 mice to produce antibodies against 
rat MOG that recognize MOG on the cell surface 
seems to be caused by the MHC class II haplo-
type H-2b [Bourquin et al. 2003]. This animal 
model has unfolded interesting differences between 
human and rodent MOG. Immunizing with 
human MOG, instead of rat MOG, leads to B-cell 
dependent EAE in these mice [Marta et al. 2005]. 
Although anti-MOG antibodies are generated 
in both cases, only antibodies generated against 
human MOG, but not those generated against rat 
MOG, are pathogenic and cause EAE upon trans-
fer to recipient mice. B-cell-independent EAE, in 
contrast, cannot be generated with human MOG 
in these mice, because the encephalitogenic T-cell 
response is dependent on a serine at position 42, 
where human MOG comprises a proline [Oliver 
et al. 2003]. Substituting proline with serine in 
human MOG allows B-cell-independent EAE 
induction with the human MOG mutant in 
C57Bl/6 mice [Marta et al. 2005].
Using anti-MOG-antibodies, a two-hit model for 
the induction of demyelination was developed. 
Encephalitogenic T cells initiate an inflammation 
and compromise the integrity of the blood–brain 
barrier. Anti-MOG antibodies are then able to 
access the CNS and mediate demyelination 
[Linington et al. 1988; Schluesener et al. 1987]. 
The two-hit model is also supported by experi-
ments with mice carrying a MOG-specific trans-
genic B-cell receptor or T-cell receptor (TCR): 
C57Bl/6 mice with a knock-in of the H chain of 
the pathogenic MOG-specific mAb 8-18C5 were 
generated [Litzenburger et al. 1998]. These mice 
have high titers of functional autoreactive MOG-
specific B cells and serum antibodies but the mice 
do not develop spontaneous EAE. Upon a slight 
challenge with encephalitogenic T cells, a fulmi-
nant demyelination develops [Litzenburger et al. 
1998]. A spontaneous relapsing–remitting mouse 
has been developed [Pollinger et al. 2009]. These 
transgenic SJL/J mice carry a TCR specific for 
the MOG peptide 92-106 and develop EAE with 
a high frequency. The mice produce MOG-
specific antibodies; depletion of B cells with an 
anti-CD20 mAb suppresses spontaneous EAE 
development. MOG-deficient TCR transgenic 
mice, in contrast, do not produce anti-MOG 
antibodies and do not develop relapsing–remit-
ting EAE [Pollinger et al. 2009].
Anti-(AQP)-4 antibodies from NMO-patients 
have been shown to induce lesions in the CNS of 
mice and rats after opening of the blood–brain 
barrier by encephalitogenic T cells [Bennett et al. 
2009; Bradl et al. 2009; Kinoshita et al. 2009]. 
When injected directly into the brain together 
with complement, rather than peripherally, these 
anti-(AQP)-4 antibodies are even able to induce 
lesions in mice lacking T cells [Saadoun et al. 
2011].
Also in primates, such as common marmosets 
(Callithrix jacchus), MOG immunization induces 
demyelinating antibodies and encephalitogenic 
T cells [‘t Hart et al. 2004]. Immunization of 
C. jacchus with myelin basic protein (MBP) 
results in clinically mild EAE without demyelina-
tion. Subsequent passive transfer of IgG against 
whole white matter causes demyelination and 
clinical aggravation, this effect is also achieved 
by passive transfer of either polyclonal antirat 
MOG antibodies or the anti-MOG mAb 8-18C5 
[Genain and Hauser, 1996]. Immunizing mar-
mosets with either the extracellular domain of rat 
MOG or synthetic 20-mer peptides revealed that 
only antibodies generated against the protein, but 
not against the peptides, cause demyelination 
and severe EAE in marmosets [von Budingen 
et al. 2002].
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Structure, abundance and localization 
of MOG
MOG is a quantitatively minor component of 
CNS myelin (less than 0.05% of all CNS myelin 
proteins) but its localization on the outermost sur-
face of myelin [Brunner et al. 1989] makes it acces-
sible for antibodies (Figure 1). Other more 
abundant myelin components, such as myelin basic 
protein, are inaccessible for antibodies. Rat MOG 
together with the Fab fragment of the mAb 8-18C5 
[Breithaupt et al. 2003] and mouse MOG 
[Clements et al. 2003] have been crystallized. The 
demyelinating mAb 8-18C5 recognizes two resi-
dues (His103 and Ser 104) at the membrane-distal 
surface of MOG [Breithaup et al. 2008]. MOG fea-
tures an IgV-like fold with a single glycosylation site 
(Asn-31). Similarities in the amino acid sequence 
and in the three-dimensional structure of MOG 
and the milk protein butyrophilin (BTN) put for-
ward a role for BTN in the sensitization of T and B 
cells against MOG [Breithaupt et al. 2008; 
Guggenmos et al. 2004].
The exact function of MOG remains unclear but 
its structure and localization suggest a role as 
an adhesion molecule, possibly gluing CNS mye-
lin fibers together [Clements et al. 2003]. MOG 
itself is also able to bind the complement compo-
nent C1q and might therefore regulate the classi-
cal complement pathway [Johns and Bernard, 
1997]. A recent study [Cong et al. 2011] showed 
that MOG might also function as a host cell 
receptor for the rubella virus. A MOG knockout 
mouse, however, showed no obvious phenotype 
Figure 1. Distribution of central nervous system (CNS) myelin proteins. A neuron with a myelinated axon 
is depicted. Myelin enwraps the axon at intervals called internodes omitting small openings termed nodes 
of Ranvier. Adjacent to the nodes of Ranvier are the paranode and the juxtaparanode. All four zones have a 
characteristic protein composition, as depicted in the upper part of the picture. At th nodes of Ranvier, Neurofascin 
186 (NF186) supports the clustering of Na+ channels. To allow saltatory conduction, the nodal Na+ channels are 
separated from the juxtaparanodal K+ channels via the paranode, where the myelin protein Neurofascin 155 
(NF155) binds tightly to the axonal complex of Contactin-1 and Contactin-associated protein (Caspr). Connexins 
form gap junctions between myelin layers at the paranode. 2’3’-cyclic-nucleotide 3’-phosphodiesterase (CNP) is 
an abundant cytoplasmic myelin protein, predominantly found at the paranode. At the juxtaparanode, clustered 
K+ channels are associated to Caspr-2 and Contactin-2 is found both at the innermost myelin-sheath and the 
axon, allowing it to bind to itself. Typical myelin proteins are found at the internode: Proteolipid protein (PLP) 
and Myelin basic protein (MBP) are the major myelin proteins, the quantitatively minor Myelin oligodendrocyte 
glycoprotein (MOG) is found at the outermost surface of the myelin sheath. Nectin-like (NECL) adhesion proteins 
and Myelin associated glycoprotein (MAG) are found at the periaxonal space. Nogo is also predominantly found at 
the adaxonal myelin membrane, its receptor Nogo-receptor 1 (NgR1) is found at the axonal membrane.
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[Delarasse et al. 2003]. Essential features of MOG 
are summarized in Table 1.
Anti-MOG antibodies in adult MS patients: 
different detection methods and 
contradictory results
Enzyme-linked immunosorbent assay
Table 2 gives an overview over important studies 
assaying anti-MOG antibodies in patients with 
CNS inflammation and controls with different 
techniques. The first studies of anti-MOG anti-
bodies in MS patients employed enzyme-linked 
immunosorbent assay (ELISA) assays with MOG 
purified from human brain white matter to deter-
mine the anti-MOG antibody titer in patients’ 
sera and cerebrospinal fluid (CSF) [Xiao et al. 
1991]. Using this approach, anti-MOG antibod-
ies were detected in the CSF of a subset of MS 
patients, but also in the control groups. Similar 
results were obtained in a later study for which 
the extracellular domain of human MOG was 
expressed in Escherichia coli, without refolding of 
the antigen [Reindl et al. 1999]. Using native full-
length mouse MOG from transfected mammalian 
cells, anti-MOG antibodies in both MS patients 
and healthy controls were detected and it was 
shown that the levels of IgM antibodies were 
higher in patients with a first demyelinating event, 
as compared with MS patients with a relapse or 
healthy donors [Gaertner et al. 2004]. The group 
also claimed to observe a correlation of anti-
MOG IgG levels and disease activity, as those IgG 
antibodies were found to be higher in MS patients 
with a relapse or secondary progressive MS 
patients, as compared with healthy donors and 
MS patients in remission [Gaertner et al. 2004].
Seemingly healthy young adults with sera con-
taining anti-MOG IgG antibodies, as deter-
mined by ELISA using recombinant human 
MOG, were reported to have a slightly higher 
risk of developing MS, compared with matched 
controls [Wang et al. 2008]. This association 
between anti-MOG status and disease risk dis-
appeared after normalizing for the anti-EBNA 
IgG titer [Wang et al. 2008]. Another group 
[Klawiter et al. 2010] detected antibodies against 
human MOG expressed in insect cells with a 
secondary antibody recognizing all antibody iso-
types in sera and CSF of both MS patients and 
controls. The group calculated an rMOG index 
as a marker for intrathecal anti-MOG Ig produc-
tion and reported that this index was slightly 
higher in MS patients than in controls [Klawiter 
et al. 2010].
Anti-MOG antibodies were isolated by affinity 
chromatography to MOG coupled agarose and 
the binding of these antibodies to synthetic MOG 
peptides was assessed in an ELISA [Haase et al. 
2001]. Antibodies from both patients and 
Table 1. Important features of MOG.
Size 218 amino acids/27 kDa
Abundance and occurrence Restricted to CNS, on the outermost surface of myelin sheaths and 
on oligodendrocytes
 0.05% of myelin proteins
Membrane topology Single span transmembrane protein:
 - extracellular domain (amino acids 1–117)
 - one transmembrane domain
 -  one C-terminal integral membrane domain [Della Gaspera et al. 
1998]
Function Unknown.
 No phenotype in knockout mouse [Delarasse et al. 2003]. Probably 
adhesion of myelin fibers [Clements et al. 2003] or regulator of 
classical complement pathway [Johns and Bernard, 1997]. Potential 
host cell receptor of the rubella virus [Cong et al. 2011].
Structure IgV-like fold, single glycosylation site (Asn-31), one disulphide bond 
(Cys24–Cys98) [Breithaupt et al. 2003; Clements et al. 2003].
Sequence conservation More than 90% among mammals [Pham-Dinh et al. 1993].
Possible pathogenic 
relevance
Target of encephalitogenic T cells.
 Target of demyelinating Abs in many species including primates.
MOG, myelin oligodendrocyte glycoprotein; CNS, central nervous system; IgV, immunoglobulin V; Abs, antibodies.
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controls bound to several peptides, without 
showing a specific MS-associated binding pat-
tern. By comparing the binding of the same anti-
bodies to cell-bound MOG in a flow-cytometry 
assay, one out of 17 MS samples and none of the 
nine healthy controls bound MOG in its native 
conformation [Haase et al. 2001].
In a recent study [Gori et al. 2011], rat MOG 
was expressed in E. coli and refolded. The correct 
folding of the antigen was demonstrated by far-
UV circular dichroism. No antibodies in either 
MS patients or controls were detected.
Antibody binding to the extracellular domain of 
recombinant human MOG, expressed in E. coli, 
was not seen in solution, but in solid-phase, 
antibodies from both MS patients and healthy 
controls bound to the same MOG construct 
[Menge et al. 2007b]. It seems conceivable that 
the affinity of anti-MOG antibodies is not high 
enough to allow detection of antibody binding 
in solution.
Anti-MOG Ig in MS tissue
IgG from the CNS parenchyma of autopsy sam-
ples from MS patients were isolated and their 
binding to refolded E. coli MOG in solid phase 
and to in vitro translated human MOG in solution 
phase was assessed [O’Connor et al. 2005]. The 
group identified IgG binding to MOG in solid 
phase in a subgroup of MS patients, but not in the 
CSF or serum. One out of 37 MS patients and no 
controls showed binding to the solution-phase 
MOG protein [O’Connor et al. 2005]. Binding of 
immunogold-labeled MOG and MBP peptides to 
CNS tissue of MS patients and marmosets with 
MOG-induced EAE was described [Genain et al. 
1999]. The group concluded that these MOG 
peptides bind to anti-MOG antibodies present on 
the tissue. This intriguing finding awaits further 
confirmation and elaboration.
Western blot
Western blot analysis detects antibodies to dena-
tured proteins. Using this technique, antibodies 
to MOG were found in MS patients and in 
healthy controls [Lindert et al. 1999; Reindl et al. 
1999]. It had been proposed that the anti-MOG 
and anti-MBP antibody status of clinically iso-
lated syndrome (CIS) patients, as determined by 
Western blotting using MOG expressed in E. 
coli, could be predictive of the progression to MS 
[Berger et al. 2003]. In this study, patients with 
antibodies against both MBP and MOG had a 
significantly higher relapse risk, compared with 
antibody-seronegative CIS patients. These 
results were refuted by later studies [Kuhle et al. 
2007; Pelayo et al. 2007] that used the same 
methods.
Cell-based assays
To detect antibodies to native MOG, cell lines 
were transfected to express MOG on the surface. 
Binding of antibodies to this surface expressed 
MOG can be detected and quantified by fluores-
cence-activated cell sorting (FACS) or immuno-
cytochemistry [Brilot et al. 2009; Di Pauli et al. 
2011; Haase et al. 2001; Lalive et al. 2006, 2011; 
McLaughlin et al. 2009; O’Connor et al. 2007; 
Probstel et al. 2011; Zhou et al. 2006]. The first 
study [Haase et al. 2001] that used MOG-
transfected cells initially obtained MOG-binding 
IgG from 200 to 300 ml of serum using E. coli 
produced MOG for affinity purification. As 
mentioned above, antibody binding to MOG-
transfected cells was seen in material obtained 
from 1/17 MS patients and in 0/9 preparations 
from controls.
A major advance in our understanding of anti-
bodies to MOG was obtained in a study that 
analyzed acute disseminated encephalomyelitis 
(ADEM) patients along with adult MS patients 
[O’Connor et al. 2007]. ADEM is an acute disor-
der of the CNS affecting mostly children under 
the age of 10. This typically monophasic disease 
is characterized by an acute inflammation and 
demyelination of the CNS and usually succeeds 
a viral infection or vaccination [Tenembaum 
et al. 2002]. This study [O’Connor et al. 2007] 
used both cell-bound MOG and a tetramer-
based assay (see below). It showed that a propor-
tion of patients with ADEM have high antibodies 
to MOG, whereas in adult MS patients, such 
antibodies are barely detectable.
All subsequent studies that used a cell-based 
assay and included ADEM, pediatric and adult 
MS, basically confirmed this observation [Brilot 
et al. 2009; Di Pauli et al. 2011; Lalive et al. 2011; 
McLaughlin et al. 2009; Probstel et al. 2011].
A MOG tetramer radioimmunoassay
Further analysis showed that the proportion of 
anti-MOG positive children can be identified 
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with a tetramer radioimmunoassay in which four 
human MOG extracellular domains are tetramer-
ized and used to detect antibodies via immuno-
precipitation [O’Connor et al. 2007]. This 
technique is more sensitive than conventional 
solution-phase assays, as the avidity of the antigen 
is higher and it detects antibodies to the correctly 
folded MOG protein more specifically than con-
ventional ELISA, because the MOG tetramer 
does not bind antibodies to linear MOG epitopes. 
With this technique, the group was able to detect 
high levels of anti-MOG antibodies in ADEM 
patients, but hardly in MS patients and control 
groups. The tetramer radioimmunoassay and the 
cell-based assay essentially identified the same 
group of anti-MOG positive patients.
Anti-MOG antibodies in a proportion of 
pediatric MS and ADEM
Using a tetramer radioimmunoassay, antibodies 
to conformationally intact MOG were detected in 
a subset of ADEM patients and these antibodies 
are rather rare in adult-onset MS cases [O’Connor 
et al. 2007]. Anti-MOG antibodies were also 
found in the serum of a subset of pediatric MS 
cases using cells transfected with MOG-GFP 
[McLaughlin et al. 2009]. All studies analyzing 
anti-MOG reactivity in pediatric patients noted a 
higher reactivity in young children (age <10 years) 
[Brilot et al. 2009; McLaughlin et al. 2009; 
Probstel et al. 2011]. No linkage between 
anti-MOG and anti-Epstein–Barr virus (EBV) 
antibodies was seen [Selter et al. 2010]. Cells 
transfected with hMOG are significantly more 
prone to natural killer (NK)-mediated cytotoxic-
ity after incubation with purified serum IgG from 
anti-MOG positive patients, as compared with 
IgG from anti-MOG negative patients [Brilot 
et al. 2009]. Another group [Di Pauli et al. 2011] 
used immunocytochemistry to assess anti-MOG 
staining in a longitudinal study. They found a cor-
relation between a decline in antibody titers and 
full recovery in ADEM patients. In a 5-year follow 
up, all 16 ADEM patients studied showed a rapid 
decline of anti-MOG antibodies [Probstel et al. 
2011]. Strikingly, anti-MOG antibodies detected 
in the same study in pediatric MS patients persist 
in six of eight patients with fluctuations and were 
even shown to increase. High titer anti-MOG-
antibodies are also present in a proportion of chil-
dren with optic neuritis (ON) and are more 
frequent in children with recurrent ON, as com-
pared to children with monophasic ON [Rostasy 
et al. 2012].
Summarizing view on anti-MOG Ig in 
pediatric and adult MS and ADEM
Technical challenges
Taken together, a general view is emerging that 
cell-bound assays are the best suited tools for ana-
lyzing antibodies to conformationally correct 
MOG. With a cell-bound assay and with the 
tetramer assay a proportion of children with 
ADEM or MS can be identified and clearly dis-
tinguished from controls. ELISA and Western 
blotting detect antibodies to incorrectly folded or 
denatured MOG. Those antibodies are not patho-
genic, because they do not necessarily recognize 
MOG as it is present in the CNS. The disadvan-
tage of using cell-bound assays, on the other hand, 
is that the cell surface is a very complex, indefin-
able milieu, compared with an ELISA plate. This 
high complexity makes it difficult to compare the 
results of different groups working with different 
cell lines and different protocols. It would there-
fore be worthwhile to develop an ELISA assay in 
which the human MOG protein is provided in its 
correctly folded structure only.
Anti-MOG Ig in adult and childhood MS/ADEM
Antibodies against correctly folded MOG are 
preferably found in pediatric MS and ADEM 
patients. In adult MS patients, such anti-MOG 
antibodies are rarely detected. The reason for this 
phenomenon is yet uncertain, but the different 
pathogeneses of these two CNS disorders (ADEM 
and MS) might play a role. ADEM usually suc-
ceeds a viral infection or vaccination and it has 
been proposed that antibodies produced against a 
viral structure might attack the immune system 
[Menge et al. 2007a]. Another explanation for the 
absence of anti-MOG antibodies in adult MS 
patients might be that anti-MOG antibodies are 
present in a few patients at the time of initiation of 
CNS inflammation, but disappear in the follow-
ing years. A recent longitudinal study noted the 
persistence of anti-MOG IgG with fluctuations 
for a period of up to 5 years in children with MS 
[Probstel et al. 2011]. The further long-term fol-
low up of these and other anti-MOG positive 
patients will provide further insight.
Possible pathogenic relevance of anti-
MOG Ig in childhood demyelination
The formal proof of pathogenicity of human anti-
MOG IgG might require transfer experiments 
which have not yet been performed. However, the 
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features of anti-MOG IgG in pediatric demyeli-
nation strongly suggest that these antibodies are 
pathogenic. This view is based on the comparison 
with prerequisites of pathogenicity of anti-MOG 
antibodies established in animal experiments. 
First, pathogenic anti-MOG antibodies recognize 
the conformationally correct MOG in a cell-
bound assay [Brehm et al. 1999]. As discussed 
above, several groups have now identified anti-
MOG antibodies in a proportion of pediatric 
demyelination with such an assay. Second, in ani-
mal models the complement fixing ability of anti-
MOG was linked to their demyelinating activity 
[Piddlesden et al. 1993]. The pediatric anti-
MOG antibodies are mostly of the complement-
activating isotype IgG1 [McLaughlin et al. 2009; 
Probstel et al. 2011]; in vitro experiments examin-
ing their complement fixing activity in the context 
of myelin and oligodendrocytes are still missing. 
In addition to complement, antibody-dependent 
cellular cytotoxicity might also contribute to tissue 
destruction and antibody-dependent cellular cyto-
toxicity activity of human anti-MOG antibodies 
has been observed in vitro [Brilot et al. 2009]. 
Third, a breached blood–brain barrier, e.g. in the 
context of a T-cell-mediated encephalitis is crucial 
for the pathogenicity of anti-MOG antibodies, 
since anti-MOG antibodies are not pathogenic in 
the absence of CNS inflammation [Litzenburger 
et al. 1998]. Gadolinium-enhanced lesions are 
found in the majority of pediatric MS and ADEM 
patients [Poser and Brinar, 2007; Waubant et al. 
2009]. These MRI data point out the disturbed 
blood–brain barrier in pediatric demyelination 
indicating that anti-MOG antibodies will have 
access to CNS myelin.
Consequences for the therapy of anti-
MOG positive patients?
The number of drugs available for the therapy of 
inflammatory CNS diseases is increasing [Kieseier 
and Stuve, 2011]. This offers the possibility for 
further treatment optimization, provided bio-
markers are available to identify patient sub-
groups. An example is the detection of 
anti-aquaporin-4 antibodies in NMO patients. 
The presence of these autoantibodies has thera-
peutic consequences, since many observations 
support the application of anti-CD20 treatment 
in NMO patients [Pellkofer et al. 2011]. In 
contrast, IFNβ might not be the ideal treatment 
for many NMO patients, since it may worsen the 
disease [Palace et al. 2010]. This might be due to 
the induction of the B-cell survival factor BAFF 
by IFNβ [Krumbholz et al. 2008]. Up to now 
experiences with IFNβ treatment in anti-MOG 
positive patients have not been reported. It seems 
plausible that patients with anti-MOG antibodies 
rather benefit from plasma exchange or a 
B-cell-directed therapy. A reduction of anti-
MOG antibodies after B-cell-directed therapy 
would be expected, if short-lived plasma blasts 
rather than long-lived plasma cells are the source 
of these antibodies. The rapid decline of anti-
MOG Ig in ADEM patients [Probstel et al. 2011] 
suggests that in these patients the antibodies are 
derived from short-lived plasma cells.
In search for other targets
The clinical observation that a proportion of MS 
patients benefit from plasma exchange [Keegan 
et al. 2005] and the absence of a decent MOG 
reactivity in the vast majority of adult MS patients 
suggests that targets of pathogenic antibodies in 
MS have yet to be identified. In a proteomic 
approach, glycoproteins were purified from 
human myelin, separated by two-dimensional gel 
electrophoresis and probed with patients’ sera for 
antigen recognition. The purification of myelin 
glycoproteins has two reasons. First, it enhances 
the sensitivity to detect antibodies to minor com-
ponents of the myelin and second, glycoproteins 
(such as MOG) are frequently displayed on the 
cell surface and accessible for antibodies. Proteins 
recognized by patients’ Ig can be identified by 
mass spectrometry. With this approach, the 
two antigens neurofascin and contactin-2/TAG-1 
have been identified [Derfuss et al. 2009; Mathey 
et al. 2007]. These two proteins are expressed by 
both oligodendrocytes and neurons and localized 
around the node of Ranvier [Derfuss et al. 2010]. 
A mAb to neurofascin mediated axonal injury in 
an animal model [Mathey et al. 2007], while T 
cells specific for contactin-2 directed encephalitis 
to the gray matter [Derfuss et al. 2009]. Another 
group also employed two-dimensional gel elec-
trophoresis and mass spectrometry, without 
specific purification of glycoproteins, and found 
antibodies against transketolase and CNPaseI in 
the CSF of MS patients [Lovato et al. 2008]. 
Further work still has to identify the relevance of 
the reactivity to these new autoantigens for indi-
vidual patients.
Patterns of autoantibody reactivities in the serum 
and CSF of MS patients have been described 
[Quintana et al. 2008]. Only binding to artificial 
peptides, but not to correctly folded proteins are 
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observed in this study. The antigen recognition 
tested with these microarrays will therefore not 
necessarily mirror the reaction in the CNS of the 
patients and it remains open whether the detected 
antibodies, which may serve as a biomarker, are 
also pathogenic. The same might be true for lipid 
microarrays probing MS patients’ sera for binding 
to myelin sheath lipids [Kanter et al. 2006]. 
Hence, antigen microarrays can only give an idea 
of which antigens might play a role in MS.
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